Semaglutide is a lab-made version of GLP-1, a gut hormone that helps regulate appetite, and is the active ingredient in Ozempic, Rybelsus and Wegovy.1,4,5,6 It is FDA-approved. The current Wegovy label covers long-term weight reduction, lowering the risk of major cardiovascular events in adults with heart disease and obesity or overweight, and a liver disease called MASH under accelerated approval.1 Those approvals rest on large randomized trials, including a cardiovascular trial of 17,604 adults described in the label.1 FDA says compounded and other unapproved semaglutide products are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before they are marketed.10
Semaglutide at a glance
What it is
A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1
FDA status
FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.1,4,5,6
Human evidence
Large randomized, placebo-controlled trials described in the Wegovy label, covering cardiovascular events, weight and MASH.1
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is semaglutide?
Semaglutide is a lab-made peptide that mimics GLP-1, a hormone released by the gut. The Wegovy label describes it as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1
Drugs@FDA lists it as the active ingredient of three Novo Nordisk brands: Ozempic, Rybelsus and Wegovy.4,5,6
How does semaglutide work?
The label states that semaglutide binds to and activates the GLP-1 receptor, the target of the natural hormone, and that GLP-1 is a physiological regulator of appetite and calorie intake.1
The label also states that the exact mechanism behind its cardiovascular risk reduction has not been established, and that its mechanism in MASH is not fully understood.1
What do human studies show?
The Wegovy label describes the trials behind its approved uses. In the cardiovascular trial, 17,604 adults with established heart or blood-vessel disease and obesity or overweight, but no diabetes, were randomized to Wegovy or placebo alongside standard care.1
Over a median follow-up of 41.8 months, a first major cardiovascular event (cardiovascular death, non-fatal heart attack or non-fatal stroke) occurred in 6.5% of the Wegovy group and 8% of the placebo group, according to the label.1
The label reports that 31% of the Wegovy group and 27% of the placebo group permanently stopped the study drug during that trial.1
The label also describes several randomized, placebo-controlled weight trials lasting 68 or 72 weeks, including one of 1,961 adults without type 2 diabetes, and a MASH trial whose week-72 analysis included 800 adults.1
What the evidence base contains
Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.1
Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.1
Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.1
Yes. Drugs@FDA records list these original approval dates: Ozempic on December 5, 2017, Rybelsus on September 20, 2019, and Wegovy on June 4, 2021. A further Wegovy application was approved on December 22, 2025.4,5,6,7
The Wegovy label cited here (DailyMed SPL version 19, published June 30, 2026) states that Wegovy is indicated, with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain the reduction long term in adults with obesity, or overweight with a weight-related condition.1
The label limits some uses to specific Wegovy products, including use in children aged 12 and older with obesity.1
The label also lists noncirrhotic MASH with moderate to advanced liver fibrosis in adults. It states that this indication was granted under accelerated approval and that continued approval may depend on a confirmatory trial.1
On March 19, 2026, FDA announced approval of Wegovy HD for weight reduction and long-term maintenance in certain adults.2
The label carries a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. The label states that Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1
Other warnings in the label cover acute pancreatitis, gallbladder disease, low blood sugar, kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic eye complications in people with type 2 diabetes, increased heart rate and aspiration during anesthesia or deep sedation.1
In January 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove a warning about suicidal thoughts and behavior from their labels, after its review found no increased risk with GLP-1 medicines.8
FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed. Its page on unapproved GLP-1 drugs, current as of October 1, 2026, says some compounders sell salt forms such as semaglutide sodium and semaglutide acetate, which are different active ingredients from those in the approved drugs, and that FDA is not aware of any lawful basis for compounding with them.10
The same page reports 990 adverse-event reports associated with compounded semaglutide received as of May 31, 2026, and describes counterfeit Ozempic and products falsely labeled as being for research purposes or not for human consumption.10
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities, saying it found no clinical need for them to compound these drugs from bulk substances. FDA invited comments through June 29, 2026.9
Timeline
FDA approves Ozempic, the first semaglutide product, according to Drugs@FDA.4
FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.9
DailyMed publishes the Wegovy label version cited on this page.1
FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.10
What is still unknown?
Whether the cardiovascular benefit applies to lower-risk groups: the label’s trial enrolled only adults aged 45 or older with established cardiovascular disease and no diabetes.1
Whether the MASH indication will be confirmed: the label says continued approval for that use may depend on a confirmatory trial.1
Whether semaglutide causes thyroid C-cell tumors in humans, which the label says has not been determined.1
What is in compounded, counterfeit or so-called research products, which FDA says it does not review before they reach the market.10
Whether FDA will finalize its April 2026 proposal on the 503B bulks list, which remained a proposal in the sources reviewed through November 14, 2026.9
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Semaglutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Semaglutide are the records PeptideScanner has selected and published, not every registration or paper about Semaglutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence questions
Start with the question you have
Open the cited status, reviewed human evidence, unresolved limits, or profile changes.
FDA-approved as Ozempic, Rybelsus and Wegovy. The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.↗↗↗↗↗
Review source snapshots checked August 18, 2026 · Integrity checked August 19, 2026.
A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.↗↗
What the reviewed sources report
In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.↗↗
What remains unresolved?
How do benefits and harms change after discontinuation, across populations excluded from these trials, and over longer follow-up?↗↗
For adults with established cardiovascular disease and obesity or overweight, the label covers cardiovascular-risk reduction with injection or tablets. Both formulations cover weight management in adults with obesity, or overweight with a weight-related condition. Injection additionally covers weight management in children aged twelve years and older with obesity, and noncirrhotic MASH with F2–F3 fibrosis in adults. The MASH indication has accelerated approval requiring confirmation of clinical benefit; it does not apply to the tablets. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rodents, with uncertain human relevance. Contraindications include personal or family medullary thyroid carcinoma, MEN 2 and hypersensitivity. Warnings address pancreatitis, gallbladder disease, hypoglycemia with insulin or insulin secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, retinopathy complications, increased heart rate and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: a8c57f3e8cf2c89501ac3b6077dd7480fb4bf72bb0b42135078f0d3a1f20f8f8. Extracted XML SHA-256: 2f2c51a1fdf57a3a2459f340abfbe1e0283e5c8849d3a844db8c28ede302f6b3.
A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.12
Bottom line from this bounded source set
In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.12
Reviewed study record
STEP 1 weight-management trial
Design
A double-blind, randomized, placebo-controlled trial followed participants for 68 weeks alongside a lifestyle intervention.1
Population
The trial enrolled 1,961 adults with obesity, or overweight plus at least one weight-related condition, who did not have diabetes.1
Outcomes reported
Mean body-weight change at 68 weeks was -14.9% in the semaglutide group and -2.4% with placebo. Gastrointestinal events were common, and treatment discontinuation for gastrointestinal events was more frequent with semaglutide.1
Limitations
The sponsor-funded trial combined treatment with lifestyle intervention, excluded people with diabetes, and does not by itself establish outcomes after treatment stops.1
Reviewed study record
SELECT cardiovascular-outcomes trial
Design
A multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial assessed a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.2
Population
The trial enrolled 17,604 adults age 45 or older with established cardiovascular disease and overweight or obesity, but no history of diabetes.2
Outcomes reported
A primary cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group; the reported hazard ratio was 0.80. Permanent discontinuation because of adverse events occurred in 16.6% and 8.2%, respectively.2
Limitations
The sponsor-funded findings apply to people with preexisting cardiovascular disease and without diabetes; they do not answer primary prevention for lower-risk populations.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2032183. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2307563. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
On January 13, 2026, FDA requested removal of the suicidal-behavior and ideation warning from Wegovy labeling after its review found no increased risk. This records the agency’s request, not a claim that every label version has changed. FDA PDF pp. 1 ↗
More findings and the sources behind them
Selected FDA safety communications, read alongside the separately preserved product-label account and human evidence review.
What supported that finding
FDA combined 91 placebo-controlled trials involving 107,910 participants and examined a separate Sentinel claims cohort. These are class-wide analyses, not a dedicated trial of this peptide or a finding about every possible adverse effect. FDA PDF pp. 2, 3 ↗
The chemical form matters
FDA distinguishes semaglutide sodium and acetate from the active ingredient in approved drugs; it lacks information establishing the same chemical and pharmacologic properties. Evidence about an approved product should not be transferred automatically to those salts. FDA source ↗
What remains to be checked
Reconcile each current product and formulation label with subsequent safety and indication changes.
Appraise remaining eligible trial reports and follow-up studies; this update does not complete the literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
The initial Ozempic review concerns type 2 diabetes
EMA’s December 2017 assessment reports improvements in HbA1c and weight in controlled trials and a separate cardiovascular trial in people at high cardiovascular risk. It does not summarize later obesity, kidney or other indication-specific programs. EMA PDF pp. 154, 155 ↗
More findings, study links and document coverage
Cardiovascular outcomes were not uniformly improved
The review described benefit on some cardiovascular outcomes but neutral findings for cardiovascular death and all-cause death. It also cautioned against extrapolating the two-year high-risk trial to lower-risk populations. EMA PDF pp. 154, 155 ↗
Retinopathy was an observed safety signal
Serious retinopathy complications were more frequent with semaglutide in the reviewed trial, especially among participants with pre-existing retinopathy receiving insulin. EMA treated the mechanism as uncertain rather than proving a single explanation. EMA PDF pp. 147, 149, 155 ↗
Harms and duration matter alongside average benefit
Gastrointestinal adverse effects were frequent and clinically relevant. EMA also noted that two years is relatively short for chronic diabetes treatment, supporting longer follow-up rather than assuming that trial results settle every long-term risk. EMA PDF pp. 154, 155 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
European medicine records · 5 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: insulin icodec;semaglutide. EMA record ↗
Marketing authorisation: 2025-11-24. EMA metadata last updated 2026-02-12. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
5586 retrieved · 2 included · 0 excluded · 5584 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Semaglutide"[Title/Abstract] OR "Wegovy"[Title/Abstract] OR "Ozempic"[Title/Abstract] OR "Rybelsus"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 5586 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 37952131 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03574597.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 33567185 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03548935.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42738873 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42737751 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736522 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736040 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736027 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735880 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735804 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735799 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42734721 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42733032 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732962 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732434 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732089 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730175 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730115 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730051 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729808 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729683 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42728029 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42727920 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
6 retrieved · 6 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 6 of 6 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA209637 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA ANDA220314 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA213182 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA215256 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA218316 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
FDA NDA213051 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: SEMAGLUTIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
5 retrieved · 5 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/005422 — include: EMA feed product Wegovy; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/004174 — include: EMA feed product Ozempic; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/004953 — include: EMA feed product Rybelsus; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/006426 — include: EMA feed product Kayshild; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/006279 — include: EMA feed product Kyinsu; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
78 retrieved · 45 included · 0 excluded · 33 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 78 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 14075 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Public assessment report
EMA 29427 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Summary for the public
EMA 47367 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-201905 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 47769 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Public assessment report
EMA 49769 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 50994 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 53437 — include: Document linked by EMA product number; content unappraised. Rybelsus-EMEA-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 54265 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-004174-X-0021 : EPAR - Assessment report - Variation
EMA 54415 — include: Document linked by EMA product number; content unappraised. Wegovy : EPAR - Public Assessment Report
EMA 58573 — include: Document linked by EMA product number; content unappraised. Ozempic-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 58575 — include: Document linked by EMA product number; content unappraised. Rybelsus-EMEA-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 58910 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 60713 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-5422-II-0009 : EPAR - Assessment Report - Variation
EMA 61952 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-005422-II-0009 : EPAR - Assessment report - Variation
EMA 64756 — include: Document linked by EMA product number; content unappraised. Wegovy-H-C-005422-II-0017 : EPAR - Assessment report - Variation
EMA 47766 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - All Authorised presentations
EMA 47768 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Risk management plan
EMA 13667 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 47939 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 7027 — include: Document linked by EMA product number; content unappraised. Ozempic : EPAR - All Authorised presentations
EMA 69828 — include: Document linked by EMA product number; content unappraised. Rybelsus : EPAR - Medicine overview
EMA 72528 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Medicine overview
EMA 72529 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Risk management plan
EMA 72531 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - All authorised presentations
EMA 72532 — include: Document linked by EMA product number; content unappraised. Kyinsu : EPAR - Public assessment report
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
783 retrieved · 0 included · 0 excluded · 783 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Semaglutide" OR "Wegovy" OR "Ozempic" OR "Rybelsus" OR "Kayshild" OR "Kyinsu"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 783 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT00833716 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06546384 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06500143 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06015893 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06977438 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07169136 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07711548 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07627191 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05616013 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07194317 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06065540 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02863419 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05920889 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07770282 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01272973 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03548935 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05227196 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07064486 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06807970 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03631186 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07478653 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05441267 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05700877 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07720466 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04447859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Semaglutide?
FDA-approved as Ozempic, Rybelsus and Wegovy. The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.↗↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationCompleted 22Recruiting 20Not yet recruiting 15Active, not recruiting 11Enrolling by invitation 2
A phase value is unavailable here for 76 selected records; this is not counted as “no phase.”
A status value is unavailable here for 70 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
52 of 108 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 43Letter 6Case Reports 3Editorial 3Observational Study 3Research Support, Non-U.S. Gov't 3Review 3Randomized Controlled Trial 2Clinical Trial, Phase II 1Consensus Statement 1Multicenter Study 1
Bibliography fields unavailable here for 56 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
5
FDA Federal Register documents
13
DailyMed SPL versions
19
Canonical profile
Published
Profile structured data
Published
Linked dated records
290
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsTrial–publication links · 3
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.
Selected records span April 4, 2017 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.↗
PubMed lists PMID 42999829 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42977490 in Archives of disease in childhood as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗